•  
  •  
  •  
  •  

2025-12-23 12:17:11

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Aurionpro's Integro Platform to Power Global Lending Modernization for a Top Singaporean Bank
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Puravankara announces acquisition of 53-acre land parcel in Bengaluru with GDV of over Rs 4,800 crores
  • Deccan Gold Mines Ltd to invest in a tungsten project in Spain
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial

Keywords Selected:  INE703H01016

Stock Report

  • Hubtown reports robust Pre-Sales of ~Rs. 3,547 Crores as of November '25
  • Twenty Five Downtown Realty Ltd obtains RERA Registration Certificate for Tower 4 of 25 Downtown Project
  • Rare Townships Pvt Ltd obtains OC for two wings of its Rising City Project at Ghatkopar
  • Hubtown Limited updates on Transferrable Development Rights issued to the Company
  • Hubtown Ltd updates on Chembur Residential Real Estate Project
  • Rare Townships Pvt Ltd enters into development management agreement with Gopani Realty LLP
  • Hubtown Limited updates on OTS with IARC
  • Hubtown Ltd allots 72 lakh warrants
  • Hubtown Limited approves issue of convertible warrants
  • Hubtown Ltd board to consider preferential issue to promoter group
  • Hubtown Ltd board to consider rights issue

Latest Post

  • Aurionpro's Integro Platform to Power Global Lending Modernization for a Top Singaporean Bank
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Puravankara announces acquisition of 53-acre land parcel in Bengaluru with GDV of over Rs 4,800 crores
  • Deccan Gold Mines Ltd to invest in a tungsten project in Spain
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024